Entrepreneurs in the vibrant life sciences hub of Cambridge and Oxford continue to face the significant challenge of securing capital for the journey from research to market success. Since 2021, the financing landscape has shifted dramatically. Traditional venture capital has become more selective, valuations compressed and the path to series B fundraising lengthened. In response, alternative financing models have emerged which, not only provide capital, but carry other benefits such as to preserve equity, accelerate development, and/or align stakeholder interests.